TNX-1500
TNX-1500 is a crystallizable fragment-modified anti-CD154 antibody. TNX-1500 contains the hu5c8 fragment antigen-binding (Fab) domain from Ruplizumab (HY-P99315) and an IgG4 Fc region engineered to reduce FcγRIIa binding. TNX-1500 has significantly weaker binding affinity to FcγRI, FcγRIIaH, FcγRIIbF, FcγRIIIaF, and FcγRIIIaV compared to hu5c8 (Kd values: 8.7 nM, 7100 nM, 4900 nM, 8000 nM, 6000 nM respectively). TNX-1500 prolongs nonhuman primate renal allograft survival, prolongs nonhuman primate cardiac allograft survival. TNX-1500 can be used for the research of allograft rejection[1][2].
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
Human
|
CD40L |
FcγRI 8.7 nM (Kd) |
FcγRIIaH 7100 nM (Kd) |
FcγRIIbF 4900 nM (Kd) |
FcγRIIIaF 8000 nM (Kd) |
FcγRIIIaV 6000 nM (Kd) |
TNX-1500 (500 nM) does not induce platelet activation in cynomolgus monkey or human whole blood when complexed with sCD154[1].
TNX-1500 has significantly weaker binding affinity to FcγRI, FcγRIIaH, FcγRIIbF, FcγRIIIaF, and FcγRIIIaV compared to hu5c8 (KD values: 8.7 nM, 7100 nM, 4900 nM, 8000 nM, 6000 nM respectively)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
化学情報
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
[1]. Lassiter G, et al. TNX-1500, a crystallizable fragment-modified anti-CD154 antibody, prolongs nonhuman primate renal allograft survival. Am J Transplant. 2023;23(8):1171-1181. [Content Brief]
[2]. Miura S, et al. TNX-1500, a crystallizable fragment-modified anti-CD154 antibody, prolongs nonhuman primate cardiac allograft survival. Am J Transplant. 2023;23(8):1182-1193. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
TNX-1500 関連分類
HY-P991921 関連分類
Powered by Bioz
- TNX-1500
- TNX1500
- TNX 1500
- TNF Receptor
- Fc Receptor (FcR)
- FcγRIIIaF
- allograft rejection
- FcγRIIIaV
- cynomolgus monkey
- antidonor alloantibody elaboration
- nonhuman primates
- platelets
- TEFF/TREG ratio
- FcγRIIaH
- CD40
- cardiac allograft vasculopathy
- regulatory T cells
- sCD154
- kidney transplantation
- chronic rejection
- FcγRI
- CAV
- nonhuman primate heart allotransplant models
- human whole blood
- ABO blood type-compatible
- CD154
- FcγRIIbF
- effector T cells
- kidney allograft rejection
- T cell costimulation pathways
- MHC-mismatched
- Inhibitor
- inhibitor
- inhibit